The focus of obesity-management interventions should shift from percentage weight-loss targets to patient-oriented parameters such as enhancing quality of life (QoL) and function, research to be ...
Hosted on MSN
New obesity drug shows up to 22 percent weight loss
When a medicine is tested in a phase two trial, the primary aim is to determine whether the treatment works and whether it is reasonably safe. The results may point in a certain direction, but they ...
A new combination drug therapy is showing extraordinary promise in the bout against obesity, helping patients lose an average of 20 percent of their body weight in a major clinical trial. The ...
CHICAGO — CagriSema, a new weekly injection from Novo Nordisk combining the amylin analogue cagrilintide with the GLP-1 receptor agonist semaglutide, significantly reduced weight and improved glycemic ...
Novo Nordisk (NVO) is out of investors' favor in the second half of the year, and so are its peers in the obesity market. For Novo Nordisk, this period was marked by the lack of upside revisions to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results